SCHEMBL2584639

SCHEMBL2584639

CCCCCCCC/C=C\CCCCCCCC(CN)(CN)CN

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FAAH O00519 6/20 0.48
TRPV1 Q8NER1 1/20 0.48
SOAT1 P35610 2/20 0.47
CYP1A2 P05177 2/20 0.47
CYP2C19 P33261 2/20 0.47
KMT2A Q03164 2/20 0.47
MEN1 O00255 1/20 0.47
TP53 P04637 1/20 0.47
CYP3A4 P08684 1/20 0.47
KDM4E B2RXH2 2/20 0.43
TERT O14746 3/20 0.42
MAPT P10636 2/20 0.42
BLM P54132 2/20 0.42
HSD17B10 Q99714 2/20 0.42
FABP4 P15090 2/20 0.42
PTPN1 P18031 2/20 0.42
PPARG P37231 2/20 0.42
PPARD Q03181 2/20 0.42
PPARA Q07869 2/20 0.42
GMNN O75496 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10837134 0.87 FAAH (0.56) FAAHTRPV1SOAT1CYP1A2CYP2C19
SCHEMBL7544355 0.87 FAAH (0.56) FAAHTRPV1SOAT1CYP1A2CYP2C19
SCHEMBL11089446 0.85 FAAH (0.54) FAAHTRPV1SOAT1CYP1A2CYP2C19
SCHEMBL1362596 0.85 FAAH (0.54) FAAHTRPV1SOAT1CYP1A2CYP2C19
SCHEMBL22022986 0.84 KDM4E (0.50) SOAT1CYP3A4KDM4EHSD17B10FABP4
SCHEMBL9319029 0.84 FDPS (0.44) KMT2AMEN1
SCHEMBL7480260 0.82 DNM1 (0.48) KMT2AMEN1
SCHEMBL29913359 0.82 DNM1 (0.48) KMT2AMEN1
SCHEMBL9453335 0.82 DNM1 (0.48) KMT2AMEN1
SCHEMBL8952970 0.82 DNM1 (0.48) KMT2AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250099480-A1 METHODS AND PHARMACEUTICAL COMPOSITIONS FOR TREATING CANDIDA AURIS IN BLOOD CORMEDIX INC (US) 2025-03-27 US disclosed
US-12016865-B2 Methods and pharmaceutical compositions for treating candida auris in blood CORMEDIX INC. (US) 2024-06-25 US disclosed
EP-3313857-B1 POLYMER-CYCLODEXTRIN-LIPID CONJUGATES WU NIAN (US) 2021-01-06 EP disclosed
US-10835608-B2 Polymer-carbohydrate conjugates for drug delivery technology LIPOSEUTICALS INC 2020-11-17 US disclosed
EP-3727393-A2 METHODS AND PHARMACEUTICAL COMPOSITIONS FOR TREATING CANDIDA AURIS IN BLOOD CorMedix Inc. (US) 2020-10-28 EP disclosed
EP-3077006-B1 POLYMER-CARBOHYDRATE CONJUGATES FOR DRUG DELIVERY TECHNOLOGY WU NIAN (US) 2020-08-19 EP disclosed
US-20190192529-A1 METHODS AND PHARMACEUTICAL COMPOSITIONS FOR TREATING CANDIDA AURIS IN BLOOD CORMEDIX INC. 2019-06-27 US disclosed
US-10064954-B2 Polymer-cyclodextrin-lipid conjugates LIPOSEUTICALS INC 2018-09-04 US disclosed
EP-2673000-B1 POLYMER-CARBOHYDRATE-LIPID CONJUGATES WU NIAN (US) 2018-05-16 EP disclosed
EP-3313857-A1 POLYMER-CYCLODEXTRIN-LIPID CONJUGATES Wu, Nian (US) 2018-05-02 EP disclosed
EP-2673000-A2 POLYMER-CARBOHYDRATE-LIPID CONJUGATES Wu, Nian (US) 2013-12-18 EP disclosed
WO-2013003306-A1 PHARMACEUTICAL COMPOSITIONS FOR PARENTERAL ADMINISTRATION WU NIAN (US) 2013-01-03 WO disclosed
US-20130004592-A1 PHARMACEUTICAL COMPOSITIONS FOR PARENTERAL ADMINISTRATION LIPOSEUTICALS, INC. 2013-01-03 US disclosed
US-8304565-B2 PEG-lipid conjugates for liposomes and drug delivery BIOZONE LABORATORIES INC. 2012-11-06 US disclosed
WO-2012109112-A2 POLYMER-CARBOHYDRATE-LIPID CONJUGATES WU NIAN (US) 2012-08-16 WO disclosed
WO-2012109052-A1 POLYMER-CARBOHYDRATE-LIPID CONJUGATES WU NIAN (US) 2012-08-16 WO disclosed
US-20120202979-A1 POLYMER-CARBOHYDRATE-LIPID CONJUGATES LIPOSEUTICALS, INC. 2012-08-09 US disclosed
US-20120202890-A1 POLYMER-CARBOHYDRATE-LIPID CONJUGATES WU NIAN (US) 2012-08-09 US disclosed
WO-2011139343-A2 AMINO ACID LINKED PEG-LIPID CONJUGATES WU NIAN (US) 2011-11-10 WO disclosed
US-20100076209-A1 PEG-lipid conjugates for liposomes and drug delivery BIOZONE LABORATORIES INC. 2010-03-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100076209-A1 PEG-lipid conjugates for liposomes and drug delivery DAGLA, DAGLB, DGKG FAAH 190/4885TRPV1 3253/4885SOAT1 401/4885
US-10835608-B2 Polymer-carbohydrate conjugates for drug delivery technology LIPC, FABP4, CETP FAAH 39/4885TRPV1 3117/4885SOAT1 208/4885
US-20130004592-A1 PHARMACEUTICAL COMPOSITIONS FOR PARENTERAL ADMINISTRATION LIPC, CETP, UGCG FAAH 1215/4885TRPV1 4452/4885SOAT1 488/4885
US-10064954-B2 Polymer-cyclodextrin-lipid conjugates CETP, FABP4, PLIN3 FAAH 549/4885TRPV1 2624/4885SOAT1 97/4885
US-20120202890-A1 POLYMER-CARBOHYDRATE-LIPID CONJUGATES LIPC, FUT6, UGCG FAAH 296/4885TRPV1 2912/4885SOAT1 293/4885
US-20120202979-A1 POLYMER-CARBOHYDRATE-LIPID CONJUGATES LIPC, FUT6, UGCG FAAH 296/4885TRPV1 2912/4885SOAT1 293/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.